SCHEMBL3314787

SCHEMBL3314787

COc1ccc(C2=NN(S(C)(=O)=O)C(c3c(F)cccc3Cl)C2)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.61
RAB9A P51151 5/20 0.61
NPC1 O15118 4/20 0.61
ALDH1A1 P00352 10/20 0.61
LMNA P02545 3/20 0.48
MAPT P10636 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
ESR1 P03372 1/20 0.46
XBP1 P17861 1/20 0.46
KMT2A Q03164 5/20 0.44
MEN1 O00255 3/20 0.44
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA12 O43570 1/20 0.42
CA9 Q16790 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAOA P21397 1/20 0.42
HTT P42858 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3318241 0.84 KDM4E (0.66) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL3315221 0.78 RAB9A (0.78) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL3315214 0.78 KDM4E (0.66) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL3319198 0.76 RAB9A (1.00) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL3311094 0.76 RAB9A (0.83) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL3314967 0.76 ALDH1A1 (1.00) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL3315128 0.73 RAB9A (0.78) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL3314124 0.73 KMT2A (0.71) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL3312505 0.73 KMT2A (0.63) KDM4ERAB9ANPC1ALDH1A1LMNA
SCHEMBL23052395 0.72 ALDH1A1 (0.66) KDM4ERAB9ANPC1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
WO-2008045663-A2 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS KALYPSYS, INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS PDE4A, PDE4B, PDE4C KDM4E 332/4885RAB9A 2140/4885NPC1 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.